Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Closed Recruiting

  • METADUR

    An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.

    Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Dr. Lillian Siu
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT02811497

  • PRIMED

    Window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative mocetinostat and durvalumab. Eligible Tumour Type(s): squamous cell carcinoma of the oral cavity

    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-House
    Principal Investigator: Dr. Lillian Siu
    NCT#: NCT02993991
  • Role of microbiome as a biomarker in loco-regionally-advanced oropharyngeal squamous cell carcinoma (ROMA)
    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-house
    Principal Investigator: Drs. Lillian Siu and Anna Spreafic
    NCT#: N/A
  • Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-house
    Principal Investigator: Dr. Lillian Siu
    NCT#: NCT03575598
  • Tumor Immunotherapy and MicrobiomE Analysis Project (TIME)
    Eligible Tumour Type(s): Metastatic Melanoma
    Sponsor: In-house
    Principal Investigator: Dr. Marcus Butler
    NCT#: N/A
  • Role of Microbiome as a Biomarker in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (ROMA LA-OPSCC-2)
    Eligible Tumour Type(s): Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
    Sponsor: In-house
    Principal Investigator: Dr. Anna Spreafico
    NCT#: NCT03838601

    https://clinicaltrials.gov/ct2/show/NCT03838601

  • TILs-001-DC

    A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer

    Eligible Tumour Type(s): Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT01883297

    https://clinicaltrials.gov/ct2/show/NCT01883297

  • TILs-002-MEL

    Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.

    Eligible Tumour Type(s): Metastatic Melanoma
    Sponsor: In-House
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT01883323

    https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1

Pages